Exclusive: Valeant to drop deal-making in near term to cut debt, boost stock

NEW YORK/WINNIPEG (Reuters) - Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters.